Drugs / Dendritic Cell Vaccine
Dendritic Cell Vaccine
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT05321940 | Nov 2023 → Nov 2025 | acute lymphoblastic leukemia, acute myeloid leukemia, adult T-cell leukemia/lymphoma | Juan C. Ramos, MD | Withdrawn | No outcome recorded |
| Phase 1 | NCT05809752 | Aug 2023 → Aug 2026 overdue | HER2 positive breast carcinoma, neoplastic meningitis, triple-negative breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05767684 | Jun 2023 → Mar 2025 | refractory malignant neoplasm | National Health Research Institutes, Taiwan | Unknown | No outcome recorded |
| Phase 1 | NCT02010606 | Jan 2014 → Jan 2019 | astrocytoma (excluding glioblastoma), brain neoplasm, glioblastoma | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01946373 | Oct 2013 → Dec 2025 | melanoma | Karolinska University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT01902771 | Sep 2013 → Oct 2016 | brain cancer, glioblastoma | Edward Ziga | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01808820 | Aug 2013 → Nov 2018 | anaplastic astrocytoma, glioblastoma | Macarena De La Fuente, MD | Completed | No outcome recorded |
| Phase 1 | NCT01792505 | Oct 2009 → Nov 2014 | malignant glioma | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00796770 | Nov 2008 → Sep 2011 | HIV infectious disease | Baylor Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00492947 | Jun 2007 → Jun 2010 | head and neck squamous cell carcinoma | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 1 | NCT00576446 | Apr 2007 → May 2012 | malignant glioma | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00700167 | Sep 2001 → Apr 2011 | melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01197625 | Sep 2010 → Sep 2024 | prostate cancer | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00056134 | Oct 2002 → Oct 2011 | cutaneous melanoma | University Hospital Erlangen | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06805656 | Jul 2026 → Jan 2027 expected | HIV infectious disease | Federal University of São Paulo | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01413295 | Aug 2011 → Sep 2014 | colorectal neoplasm | Fundacion Clinic per a la Recerca Biomédica | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06749925 | Jan 2026 → Jan 2028 expected | glioblastoma | University of Sao Paulo General Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02961829 | Jul 2015 → Mar 2019 | HIV infectious disease | Federal University of São Paulo | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00402142 Comparator | Nov 2006 → Dec 2011 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell Vaccine | “The purpose of this study is to test the safety and effects of a special type of a cancer vaccine called a 'dendritic cell vaccine' in patients with either newly diagnosed or...” NCT02010606 ↗ |
| Known as | BIIR/ANRS-HIVax-001 | “vaccination with ex vivo generated interferon-alpha dendritic cells loaded with HIV-1 lipopeptides and activated with lipopolysaccharide (BIIR/ANRS-HIVax-001, the DC vaccine product).” NCT00796770 ↗ |
| Known as | DCV | “The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given...” NCT05809752 ↗ |
| Known as | MDDCT | “We developed a personalized Monocyte-Derived Dendritic-cell Therapy (MDDCT) for HIV-infected individuals on suppressive antiretroviral treatment and evaluated HIV-specific...” PMID 35022035 ↗ Jan 2022 |
| Known as | Monocyte-Derived Dendritic-cell Therapy | “We developed a personalized Monocyte-Derived Dendritic-cell Therapy (MDDCT) for HIV-infected individuals on suppressive antiretroviral treatment and evaluated HIV-specific...” PMID 35022035 ↗ Jan 2022 |
| Action | Activate | “The goal of this dendritic cell vaccine is to activate a patient's own immune system against their tumor.” NCT02010606 ↗ |
| Modality | Vaccine | “Dendritic cell vaccine plus denileukin difitox” NCT00056134 ↗ |
| Route | Subcutaneous | “Patients receive 4 pulsed DC vaccinations subcutaneously (SC)” NCT00056134 ↗ |